M2 macrophages mediate sorafenib resistance by secreting HGF in a feed-forward manner in hepatocellular carcinoma.

Br J Cancer · 2019 · PMC6738111 · PMID 31130723

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

59 Importantly, a recent biomarker analysis of samples from the pivotal phase III trial of sorafenib showed a trend toward improved survival in patient with a lower pre-treatment plasma HGF concentration, 60 highlighting the clinical importance of tumour-associated M2 macrophages and HGF in tumour response to sorafenib.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.